99 related articles for article (PubMed ID: 20037485)
21. The carcinostatic and proapoptotic potential of 4-hydroxynonenal in HeLa cells is associated with its conjugation to cellular proteins.
Sovic A; Borovic S; Loncaric I; Kreuzer T; Zarkovic K; Vukovic T; Wäg G; Hrascan R; Wintersteiger R; Klinger R; Zurak N; Schaub RJ; Zarkovic N
Anticancer Res; 2001; 21(3B):1997-2004. PubMed ID: 11497289
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
23. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
24. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
26. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells.
Gruber BM; Anuszewska EL; Bubko I; Gozdzik A; Priebe W; Fokt I
Anticancer Res; 2005; 25(3B):2193-8. PubMed ID: 16158963
[TBL] [Abstract][Full Text] [Related]
27. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
28. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
29. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
Shen J; Zhang W; Wu J; Zhu Y
Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
Yu L; Wu WK; Li ZJ; Liu QC; Li HT; Wu YC; Cho CH
Mol Pharmacol; 2009 Jun; 75(6):1364-73. PubMed ID: 19264847
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
32. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
33. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells.
Ishibashi M; Bottone FG; Taniura S; Kamitani H; Watanabe T; Eling TE
Exp Cell Res; 2005 Jan; 302(2):244-52. PubMed ID: 15561105
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene.
Kim JH; Chang JH; Rhee KH; Yoon JH; Kwon SH; Song K; Lee KW; Cho CI; Jeon JH; Kim KS
Int J Cancer; 2008 Apr; 122(8):1765-73. PubMed ID: 18076062
[TBL] [Abstract][Full Text] [Related]
35. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
[TBL] [Abstract][Full Text] [Related]
36. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
37. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
[TBL] [Abstract][Full Text] [Related]
38. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
Puhlmann U; Ziemann C; Ruedell G; Vorwerk H; Schaefer D; Langebrake C; Schuermann P; Creutzig U; Reinhardt D
J Pharmacol Exp Ther; 2005 Jan; 312(1):346-54. PubMed ID: 15501994
[TBL] [Abstract][Full Text] [Related]
39. Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant.
Wu CH; Gordon J; Rastegar M; Ogretmen B; Safa AR
Oncogene; 2002 Aug; 21(33):5160-74. PubMed ID: 12140766
[TBL] [Abstract][Full Text] [Related]
40. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
Barraud L; Merle P; Soma E; Lefrançois L; Guerret S; Chevallier M; Dubernet C; Couvreur P; Trépo C; Vitvitski L
J Hepatol; 2005 May; 42(5):736-43. PubMed ID: 15826724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
